Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy

Completed · Phase 1

Conditions studied: Chronic Hepatitis C

In brief

A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.

Key facts

Study ID

NCT00749138

Run by

Bader, Ted, M.D.

People needed

18

Starts

2008-11-01

Expected to finish

2009-10-01

Last updated by the study team

2010-03-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HCV RNA positive.
• failed standard therapy

You may not qualify if…

• Cirrhosis on biopsy
• Severe medical or psychiatric conditions that would make the evaluation difficult
• Tamoxifen is a pregnancy category D drug so pregnant women must be excluded.
• Patients with coumadin cannot be used from a drug interaction.
• Active use of alcohol or illegal substances -

Where it is running

• VA Hospital — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.